Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | USP2 | O75604 | 4/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RGS12 | O14924 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30029189 | 1.00 | DDB1 (0.47) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL30848071 | 0.88 | DDB1 (0.38) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL28237818 | 0.79 | DDB1 (0.48) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL16722620 | 0.78 | SSTR4 (0.39) | ALDH1A1CYP3A4LMNATP53THRB | |
| SCHEMBL27138457 | 0.78 | DDB1 (0.47) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL30847906 | 0.78 | DDB1 (0.47) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL27143123 | 0.78 | DDB1 (0.47) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL7572100 | 0.75 | MEN1 (0.37) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL30848080 | 0.75 | DDB1 (0.45) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL27153773 | 0.75 | DDB1 (0.45) | DDB1CRBNALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355741-B1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2022266248-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266248-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | DDB1 733/4885CRBN 325/4885ALDH1A1 3268/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | DDB1 985/4885CRBN 474/4885ALDH1A1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.